EU Authorised Representative for Medical Devices and IVDs Across Europe
For non-EU manufacturers, placing medical devices or in vitro diagnostic devices in Europe requires more than product quality, technical files and regulatory planning. Before a device can be placed on the European market, the manufacturer must appoint an EU Authorized Representative based within the European Union and formally recognised as the manufacturer’s authorised representative. This role is essential under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation because regulators need a responsible local party who can communicate, provide documentation and support compliance activities when required. An eu-authorized-representative is not simply a name on a label. The representative acts as the legal presence of a non-EU manufacturer and plays an important role in maintaining market access, regulatory confidence and post-market accountability.
Why an EU Authorized Representative Is Required
European regulations for medical devices aim to safeguard patients, healthcare providers and users by ensuring every product entering the market has a defined chain of responsibility. When a manufacturer is based outside the European Union, regulators cannot always deal with that manufacturer directly in the same practical way they would with a local company. This is exactly where the EU Authorized Representative becomes essential. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without designating an authorised representative, a non-EU manufacturer is not permitted to place medical devices or IVDs on the European market. This applies to a wide range of products, from simple low-risk devices to complex diagnostic technologies. The requirement exists before market entry, which means the representative must be appointed early in the compliance process rather than treated as a final administrative step. For companies preparing for European distribution, selecting the right EU Authorized Representative for Medical Devices and IVDs can significantly influence registration readiness, document management and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The relationship between the manufacturer and the EU Authorized Representative must be established through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a key compliance document because it sets out the scope of representation, responsibilities, communication duties and actions required if compliance concerns arise.
A vague or poorly prepared mandate can create uncertainty at the worst possible time, especially during an authority request, inspection, complaint review or corrective action. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. Therefore, the mandate must be carefully drafted and reviewed before registration or market entry begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must be displayed on the device label, packaging or associated product information in accordance with applicable regulations. This allows authorities, distributors, healthcare professionals and users to identify the local representative linked to the device. It also strengthens the representative’s role as the official European contact for a manufacturer based outside the European Union.
Accurate labelling is essential because incorrect or missing representative details can lead to compliance issues and possible delays in market access. Manufacturers should ensure that their artwork, instructions, declarations and registration information are aligned before products are released. If the representative changes, labelling and registration details may also need to be updated in a controlled and timely manner.
Documentation Review and Availability
A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This includes checking that the EU Declaration of Conformity exists, that technical documentation has been compiled and that the manufacturer has followed an appropriate conformity assessment route for the device type and risk class.
The representative may also need to hold or have access to copies of technical documentation, declarations and Notified Body certificates. These documents must be available for inspection by Competent Authorities for the required retention period after the last device has been placed on the market. This makes document control a central part of the relationship between manufacturer and representative. Manufacturers should keep records updated and ensure the representative can respond promptly to regulatory requests.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative serves as the formal communication link between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also communicate with Notified Bodies when required, especially where certificates, conformity assessment or corrective actions are involved.
This communication role requires more than forwarding messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Delayed or incomplete responses can create serious issues for manufacturers, including market restrictions or further regulatory review. Therefore, manufacturers should partner with a representative who has strong regulatory expertise and well-defined internal systems.
Post-Market Surveillance and Incident Support
Compliance for medical devices does not stop once the product reaches the market. After a device is in circulation, manufacturers must continuously monitor performance, complaints, incidents and safety indicators. The EU Authorized Representative has a role in supporting this post-market responsibility by passing complaints and incident information to the manufacturer without delay.
This is especially important when information comes from clinicians, patients, users, distributors or authorities. Timely communication helps the manufacturer assess whether further investigation, reporting, field safety action or corrective action is needed. A strong representative understands that post-market surveillance is not just paperwork. It is part of patient safety, product improvement and ongoing regulatory trust.
Registration Responsibilities and EUDAMED
Under European regulatory systems, manufacturer and representative details must be registered as required. The EU Authorized Representative may assist with registering both manufacturer and representative data in EUDAMED. Accurate registration enables authorities to identify responsible entities, review device data and maintain market supervision.
Manufacturers should prepare complete company details, device information, certificates and declarations before registration activities begin. Any mismatch between labelling, declarations, technical documentation and registration records may lead to delays or compliance concerns. The representative’s involvement helps ensure that required information is properly aligned and available when needed.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If serious non-compliance occurs and the manufacturer does eu-authorized-representative not correct the issue, the representative may need to end the mandate and inform relevant authorities and the Notified Body where applicable. This responsibility highlights that the role extends beyond administrative tasks.
The representative holds legal responsibility and cannot overlook serious compliance breaches. Manufacturers should therefore view the representative as a regulatory partner rather than a passive provider. Open communication, timely document updates and clear responsibility sharing help prevent misunderstandings and reduce risk during the product life cycle.
Choosing the Right EU Authorized Representative
Selecting an EU Authorized Representative should be done with care. Manufacturers should look for regulatory competence, experience with medical devices and IVDs, document handling capability, clear response procedures and a strong understanding of European requirements. The representative should be able to support communication with authorities, maintain records and guide the manufacturer on practical compliance expectations.
Cost should not be the only factor. An ineffective representative may lead to delays, communication gaps and increased risk, whereas a strong representative can support confidence during market entry and beyond. The correct selection provides non-EU manufacturers with a reliable European presence and enables smoother regulatory management.
Conclusion
An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role includes legal representation, documentation availability, authority communication, complaint handling, registration support and action in cases of serious non-compliance. Under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is not optional and should be completed before market placement begins. By selecting a capable EU Authorized Representative for Medical Devices and IVDs, manufacturers can enhance compliance, protect patient safety and establish a solid foundation for long-term European market access.